FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385557405> ?p ?o ?g. }

• W4385557405 endingPage "1425" @default.
• W4385557405 startingPage "1413" @default.
• W4385557405 abstract "Dorzagliatin is a first-in-class small molecule glucokinase activator (GKA) that improves pancreatic insulin secretion behavior and regulates hepatic glucose conversion in a glucose concentration-dependent manner. The primary objective of this study was to develop a population pharmacokinetic model of dorzagliatin to evaluate the influence of covariates, such as demographic characteristics and liver and kidney function, on the pharmacokinetics of dorzagliatin and provide a basis for medication guidance.The pharmacokinetic data of dorzagliatin in this study came from six clinical trials. Based on the combined data, a population pharmacokinetic model of dorzagliatin was established using NONMEM software (ICON, MD, USA, version 7.4.3). The algorithm used was first-order conditional estimation with interaction (FOCEI). The dorzagliatin population pharmacokinetic modeling analysis included 1062 subjects and 7686 observable concentrations. Covariates, including age (AGE), sex (GEND), body weight (TBW), body mass index (BMI), body surface area (BSA), albumin (ALB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (CR), creatinine clearance (CRCL), and total bilirubin (TBIL), were screened using the forward-backward method. Model evaluation was performed using goodness-of-fit plots, prediction corrected visual prediction check (pcVPC), and bootstrap.Concentration data of dorzagliatin in the dose range were best characterized by a two-compartment model with sequential zero-order then first-order absorption and first-order elimination. The final model estimated dorzagliatin data for typical male subjects (69 kg body weight, 18 U/L AST and 55 years old); the apparent total clearance (CL/F) was 10.4 L/h, apparent volume of central compartment distribution (Vc/F) was 80.6 L, inter-compartmental clearance (Q/F) was 3.02 L/h, apparent volume of peripheral compartment distribution (Vp/F) was 26.5 L, absorption rate constant (Ka) was 3.29 h-1, and duration of zero-order absorption (D1) was 0.418 h. The inter-individual variation of CL/F, Vc/F, Vp/F, and D1 was 22.5%, 14.9%, 48.8%, and 82.8%, respectively.The two-compartment linear pharmacokinetic model with zero- and first-order sequential absorption adequately described the pharmacokinetic characteristics of dorzagliatin. Body weight, aspartate aminotransferase, and age had a statistically significant effect on the CL/F of dorzagliatin. Body weight and sex had a statistically significant effect on Vc/F. However, considering the clinically insignificant changes in the magnitude of steady-state exposure caused by these covariates, as well as the minimal changes in the steady-state exposure for individuals with mild and moderate impaired hepatic function and all stages of renal impairment, dose adjustments based on the tested covariates or for specific populations are deemed unnecessary." @default.
• W4385557405 created "2023-08-04" @default.
• W4385557405 creator A5007765587 @default.
• W4385557405 creator A5030691366 @default.
• W4385557405 creator A5046074895 @default.
• W4385557405 creator A5058684135 @default.
• W4385557405 creator A5062749373 @default.
• W4385557405 creator A5065678258 @default.
• W4385557405 creator A5073661044 @default.
• W4385557405 date "2023-08-03" @default.
• W4385557405 modified "2023-10-08" @default.
• W4385557405 title "Population Pharmacokinetic Analysis of Dorzagliatin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus" @default.
• W4385557405 cites W1965479467 @default.
• W4385557405 cites W1973097930 @default.
• W4385557405 cites W2021854043 @default.
• W4385557405 cites W2042553471 @default.
• W4385557405 cites W2058734479 @default.
• W4385557405 cites W2070013574 @default.
• W4385557405 cites W2094019929 @default.
• W4385557405 cites W2345694792 @default.
• W4385557405 cites W2799564070 @default.
• W4385557405 cites W2801191096 @default.
• W4385557405 cites W3211248370 @default.
• W4385557405 cites W4280522030 @default.
• W4385557405 cites W4280562645 @default.
• W4385557405 cites W4310379805 @default.
• W4385557405 doi "https://doi.org/10.1007/s40262-023-01286-8" @default.
• W4385557405 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37537410" @default.
• W4385557405 hasPublicationYear "2023" @default.
• W4385557405 type Work @default.
• W4385557405 citedByCount "0" @default.
• W4385557405 crossrefType "journal-article" @default.
• W4385557405 hasAuthorship W4385557405A5007765587 @default.
• W4385557405 hasAuthorship W4385557405A5030691366 @default.
• W4385557405 hasAuthorship W4385557405A5046074895 @default.
• W4385557405 hasAuthorship W4385557405A5058684135 @default.
• W4385557405 hasAuthorship W4385557405A5062749373 @default.
• W4385557405 hasAuthorship W4385557405A5065678258 @default.
• W4385557405 hasAuthorship W4385557405A5073661044 @default.
• W4385557405 hasBestOaLocation W43855574051 @default.
• W4385557405 hasConcept C112705442 @default.
• W4385557405 hasConcept C126322002 @default.
• W4385557405 hasConcept C134018914 @default.
• W4385557405 hasConcept C139254425 @default.
• W4385557405 hasConcept C159641895 @default.
• W4385557405 hasConcept C2776239304 @default.
• W4385557405 hasConcept C2777501473 @default.
• W4385557405 hasConcept C2780221984 @default.
• W4385557405 hasConcept C2780306776 @default.
• W4385557405 hasConcept C2908647359 @default.
• W4385557405 hasConcept C3020755252 @default.
• W4385557405 hasConcept C71924100 @default.
• W4385557405 hasConcept C90924648 @default.
• W4385557405 hasConcept C98274493 @default.
• W4385557405 hasConcept C99454951 @default.
• W4385557405 hasConceptScore W4385557405C112705442 @default.
• W4385557405 hasConceptScore W4385557405C126322002 @default.
• W4385557405 hasConceptScore W4385557405C134018914 @default.
• W4385557405 hasConceptScore W4385557405C139254425 @default.
• W4385557405 hasConceptScore W4385557405C159641895 @default.
• W4385557405 hasConceptScore W4385557405C2776239304 @default.
• W4385557405 hasConceptScore W4385557405C2777501473 @default.
• W4385557405 hasConceptScore W4385557405C2780221984 @default.
• W4385557405 hasConceptScore W4385557405C2780306776 @default.
• W4385557405 hasConceptScore W4385557405C2908647359 @default.
• W4385557405 hasConceptScore W4385557405C3020755252 @default.
• W4385557405 hasConceptScore W4385557405C71924100 @default.
• W4385557405 hasConceptScore W4385557405C90924648 @default.
• W4385557405 hasConceptScore W4385557405C98274493 @default.
• W4385557405 hasConceptScore W4385557405C99454951 @default.
• W4385557405 hasIssue "10" @default.
• W4385557405 hasLocation W43855574051 @default.
• W4385557405 hasLocation W43855574052 @default.
• W4385557405 hasOpenAccess W4385557405 @default.
• W4385557405 hasPrimaryLocation W43855574051 @default.
• W4385557405 hasRelatedWork W10390674 @default.
• W4385557405 hasRelatedWork W1868808160 @default.
• W4385557405 hasRelatedWork W1888057860 @default.
• W4385557405 hasRelatedWork W2040885378 @default.
• W4385557405 hasRelatedWork W2055813798 @default.
• W4385557405 hasRelatedWork W2087821742 @default.
• W4385557405 hasRelatedWork W2123003250 @default.
• W4385557405 hasRelatedWork W2349082311 @default.
• W4385557405 hasRelatedWork W2397635577 @default.
• W4385557405 hasRelatedWork W4285256702 @default.
• W4385557405 hasVolume "62" @default.
• W4385557405 isParatext "false" @default.
• W4385557405 isRetracted "false" @default.
• W4385557405 workType "article" @default.